{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombopenia&page=2",
    "query": {
      "condition": "Thrombopenia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombopenia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T07:08:24.106Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02401061",
      "title": "PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "PRTX-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Protalex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-09",
      "completion_date": "2019-06-04",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Farmington Hills, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401061"
    },
    {
      "nct_id": "NCT00195624",
      "title": "Alemtuzumab to Treat Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia, Refractory",
        "Severe Aplastic Anemia, Relapse"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab (Campath )",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "2 Years to 110 Years"
      },
      "enrollment_count": 47,
      "start_date": "2005-09-15",
      "completion_date": "2018-10-15",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195624"
    },
    {
      "nct_id": "NCT00251277",
      "title": "Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2005-11",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2012-11-15",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00251277"
    },
    {
      "nct_id": "NCT00442871",
      "title": "Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Purpura, Thrombocytopaenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2006-09-28",
      "completion_date": "2008-01-03",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00442871"
    },
    {
      "nct_id": "NCT04958265",
      "title": "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome"
      ],
      "interventions": [
        {
          "name": "Crovalimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "28 Days to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-11-17",
      "completion_date": "2029-05-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04958265"
    },
    {
      "nct_id": "NCT00329433",
      "title": "Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Desirudin (Iprivask™)",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2006-05",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00329433"
    },
    {
      "nct_id": "NCT00961064",
      "title": "A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-03-15",
      "completion_date": "2021-12-30",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00961064"
    },
    {
      "nct_id": "NCT07104565",
      "title": "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "INCA000585",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-12-29",
      "completion_date": "2028-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 10,
      "location_summary": "Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104565"
    },
    {
      "nct_id": "NCT03519672",
      "title": "Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-07-12",
      "completion_date": "2019-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03519672"
    },
    {
      "nct_id": "NCT04056195",
      "title": "Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "SKI-O-703",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oscotec Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-10-11",
      "completion_date": "2023-01-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-07-24T07:08:24.106Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04056195"
    }
  ]
}